Topic: antibody-drug conjugates
The treatment staved off cancer for a median of 16.4 months and shrank tumors in 61% of patients with HER2-positive breast cancer.
AbbVie’s second entry on this list is Rova-T, an antibody-drug conjugate that finally outstayed its welcome after flunking a phase 3 study in small-cell lung cancer, a difficult-to-treat cancer linked to smoking.
High-grade gliomas are one of the toughest tumors to treat, and the first entrant on our alphabetical list—AbbVie’s antibody-drug conjugate Depatux-M—is one of at least three drugs that failed to hit the mark in this highly aggressive form of brain cancer in 2019.
Immunomedics has had a long and troubled road in the past few years that has included losing much of its C-suite after an FDA rejection.
Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.
Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.
The case centers on linker technology used in antibody-drug conjugates (ADCs) including Daiichi’s AstraZeneca-partnered DS-8201.
AstraZeneca landed the PDUFA date for [fam-] trastuzumab deruxtecan after the FDA accepted its approval submission for priority review.
A week after Sarah Boyce exited Akcea, she's at the helm of Avidity Biosciences, a company aiming to take antibody-drug conjugates to the next level.
Astellas and Seattle Genetics’ antibody-drug conjugate is at it again. With Merck’s Keytruda, the med shrank 71% of bladder tumors, new data show.